Ina press release published by the company, they indicate that a human trial has already completed proving the basic technology can deliver insulin to people with Type 1 diabetes.
According to Dr Esra Ogru, COO, the ability of the Phosphagenics’ TPM technology to deliver large proteins, such as insulin, through the skin and into the blood stream “has potential to reduce the number of invasive injections per day,” she said. “Our aim is to provide a basal level of insulin to people with diabetes over a sustained period. Currently basal levels of insulin are provided by injections. Basal insulin is the fastest growing segment of the insulin market.”
I can only hope that this time we actually get beyond the research and into a final product. We seem to have heard too many times that this type of technology is about to get into the market but we are still waiting.